Clinical Trial Update: UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating UB-621, a monoclonal antibody targeting herpes simplex virus, for adult recurrent genital herpes infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes

Drugs mentioned

• UB-621 (UB-621)

Snippet

Sponsor: UBP Greater China (Shanghai) Co., Ltd | Conditions: Recurrent Genital Herpes | Phase 2 | Status: UNKNOWN